These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33966598)

  • 1. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
    Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
    Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
    Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
    Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
    Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roxadustat (FG-4592) protects against ischaemia/reperfusion-induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice.
    Zhang M; Dong R; Yuan J; Da J; Zha Y; Long Y
    Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):311-318. PubMed ID: 34653291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
    Deguchi H; Ikeda M; Ide T; Tadokoro T; Ikeda S; Okabe K; Ishikita A; Saku K; Matsushima S; Tsutsui H
    Circ J; 2020 May; 84(6):1028-1033. PubMed ID: 32213720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation.
    Yang H; Wu Y; Cheng M; Zhang M; Qiu X; Liu S; Zhang M
    Nephrol Dial Transplant; 2023 Mar; 38(4):858-875. PubMed ID: 36413468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3
    Li X; Zou Y; Xing J; Fu YY; Wang KY; Wan PZ; Zhai XY
    Oxid Med Cell Longev; 2020; 2020():6286984. PubMed ID: 32051732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J; Henschel C; Chou J; Lin A; Del Balzo U
    Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT; Lo YC; Gao ZH; Wu SN
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.
    Wu M; Chen W; Miao M; Jin Q; Zhang S; Bai M; Fan J; Zhang Y; Zhang A; Jia Z; Huang S
    Clin Sci (Lond); 2021 Jul; 135(14):1707-1726. PubMed ID: 34255035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitophagy mediated by HIF-1α/FUNDC1 signaling in tubular cells protects against renal ischemia/reperfusion injury.
    Zhang W; Guo C; Li Y; Wang H; Wang H; Wang Y; Wu T; Wang H; Cheng G; Man J; Chen S; Fu S; Yang L
    Ren Fail; 2024 Dec; 46(1):2332492. PubMed ID: 38584135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
    Kabei K; Tateishi Y; Shiota M; Osada-Oka M; Nishide S; Uchida J; Nakatani T; Matsunaga S; Yamaguchi T; Tomita S; Miura K
    J Pharmacol Sci; 2020 Mar; 142(3):93-100. PubMed ID: 31866051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
    Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
    Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
    Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury.
    Kapitsinou PP; Sano H; Michael M; Kobayashi H; Davidoff O; Bian A; Yao B; Zhang MZ; Harris RC; Duffy KJ; Erickson-Miller CL; Sutton TA; Haase VH
    J Clin Invest; 2014 Jun; 124(6):2396-409. PubMed ID: 24789906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H; Wang X; Zhang X; Wang H; Jiang W
    Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury.
    Xie D; Wang J; Hu G; Chen C; Yang H; Ritter JK; Qu Y; Li N
    J Pharmacol Exp Ther; 2021 Sep; 378(3):235-243. PubMed ID: 34103333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.